Skip to main content

Table 3 Plasma AGE-levels in individuals with T1DM and a moderate to high compared with a low CAC score

From: Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification

  

Model 1

Model 2

  

Mean

95%-CI

p-value

Mean

95%-CI

p-value

Pentosidine* (nmol/mmol LYS)

CAC = 0-10

0.67

0.63 – 0.72

 

0.67

0.63 – 0.71

 

CAC > 10

0.80

0.69 – 0.92

0.034

0.81

0.70 – 0.93

0.028

CML (nmol/mmol LYS)

CAC = 0-10

105.0

101.7 – 108.2

 

104.5

101.5 – 107.5

 

CAC > 10

102.9

95.8 – 110.0

0.608

105.0

98.3 – 111.8

0.883

CEL (nmol/mmol LYS)

CAC = 0-10

14.9

14.2 – 15.5

 

14.9

14.3 – 15.5

 

CAC > 10

15.9

14.6 – 17.3

0.166

15.9

14.6 – 17.3

0.163

THP* (U/mL)

CAC = 0-10

122.2

113.5 – 131.8

 

121.6

112.7 – 131.2

 

CAC > 10

140.6

119.4 – 165.6

0.131

143.9

121.3 – 170.6

0.086

  1. Data are presented as adjusted means or geometric means* of AGEs in individuals with a CAC score of 0–10 compared to >10 in individuals with T1DM, by use of a complete case analysis.
  2. n = 135 for individuals with a calcification score of 0–10; n = 30 for individuals with a calcification score of >10.
  3. Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, SBP, DBP, BMI, WHR, pack-years of smoking, LDL, HDL, triglycerides and eGFR. CML, N(epsilon)-(carboxymethyl)lysine; CEL, N(epsilon)-(carboxyethyl)lysine; THP, tetrahydropyrimidine.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840